Table 4.
The most globally cited articles on resistance to CDK4/6 inhibitors.
| Title | First Author | Year | Journal | Local Citations (LC) | Global Citations (GC) | LC/GC ratio | Normalized Global Citations* |
|---|---|---|---|---|---|---|---|
| The Pezcoller lecture: Cancer cell cycles revisited | Sherr, Charles J. | 2000 | Cancer Research | 7 | 1074 | 0.65% | 7.01 |
| Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial | Massimo Cristofanilli | 2016 | Lancet Oncology | 211 | 919 | 22.96% | 13.82 |
| PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro | Richard S Finn | 2009 | Breast Cancer Research | 256 | 885 | 28.93% | 7.47 |
| Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer | Hortobagyi GN | 2016 | The New England Journal of Medicine | 182 | 821 | 22.17% | 12.35 |
| Treating cancer with selective CDK4/6 inhibitors | O’Leary B | 2016 | Nature Reviews Clinical Oncology | 128 | 557 | 22.98% | 8.38 |
| A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade | Livnat Jerby-Arnon | 2018 | Cell | 18 | 430 | 4.19% | 12.26 |
| An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide) | Korpal M | 2013 | Cancer Discovery | 5 | 384 | 1.30% | 7.88 |
| Cyclin-dependent kinases regulate the antiproliferative function of Smads | Matsuura I | 2004 | Nature | 13 | 379 | 3.43% | 5.26 |
| AKT/PKB Phosphorylation of p21Cip/WAF1 Enhances Protein Stability of p21Cip/WAF1 and Promotes Cell Survival | Li Y | 2002 | Journal of Biological Chemistry | 1 | 361 | 0.28% | 3.86 |
| Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer | Herrera-Abreu MT | 2016 | Cancer Research | 216 | 336 | 64.29% | 5.05 |
* Normalized Global Citations: Total citations of the article/average citations of peer articles when compared to peer papers (papers published in the same year, in the same discipline, and also in the same literature type).